PolyPid Ltd. (PYPD) Discusses the Science and Business Case for D-PLEX100 in Tackling Surgical Site Infections Transcript
Summarize this article with:
SA Transcripts157.29K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call PolyPid Ltd. (PYPD) Discusses the Science and Business Case for D-PLEX100 in Tackling Surgical Site Infections December 10, 2025 11:30 AM EST Company Participants Dikla Akselbrad - CEO & DirectorOri Warshavsky - Chief Operating Officer - US Conference Call Participants Boobalan Pachaiyappan - ROTH Capital Partners, LLC, Research DivisionSteven Wexner - MedStar Health, Inc.
Presentation Boobalan PachaiyappanROTH Capital Partners, LLC, Research Division All right. Good morning, everyone. My name is Boobalan. I'm a Managing Director and Senior Biotech analyst at ROTH Capital Partners. I specialize in emerging companies in the SMid-cap space, particularly in the pharma and biotech sectors. So I'm delighted to welcome Dr. Steven Wexner to this KOL webinar. So before that, I just wanted to invite PolyPid team as well. Just as a disclosure, PolyPid is a $78 million market cap company. They have a product which is called D-PLEX100, which we'll discuss in detail today. And then just in case, I cover PolyPid and my recommendation is a buy rating. My 12 months price target is $9 per share. So why don't we start with introductions First, Dr. Wexner, maybe you can give us a high-level introduction. I think you can do better justice to yourself than me. Steven WexnerMedStar Health, Inc. Sure, sure. So my name is Steve Wexner. I was at the Cleveland Clinic, Florida for 38 years as Chair of the Department of Colorectal Surgery and Director of the Ellen Leifer Shulman and Steven Shulman Digestive Disease Center, past President of the American Society of Colorectal Surgeons, past President of the Society of American Gastrointestinal Endoscopic Surgeons, past Vice Chair of the Board of Regent for the American College of Surgeons and a variety of other things, Editor and Chief of Surgery, one of the most important surgical journals. As of November 1, I'm the Executive Director and System Chief at Recommended For You